New York State Common Retirement Fund lessened its holdings in United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 15.2% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 62,221 shares of the biotechnology company’s stock after selling 11,189 shares during the period. New York State Common Retirement Fund’s holdings in United Therapeutics were worth $14,054,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Massmutual Trust Co. FSB ADV grew its holdings in shares of United Therapeutics by 61.4% during the second quarter. Massmutual Trust Co. FSB ADV now owns 163 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 62 shares in the last quarter. Neo Ivy Capital Management purchased a new position in United Therapeutics in the 2nd quarter worth approximately $48,000. Atlas Capital Advisors LLC bought a new position in shares of United Therapeutics in the 4th quarter worth $51,000. Hazlett Burt & Watson Inc. raised its position in shares of United Therapeutics by 24.0% during the 2nd quarter. Hazlett Burt & Watson Inc. now owns 248 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 48 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its holdings in shares of United Therapeutics by 49.6% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 196 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 65 shares during the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In other news, Director Christopher Causey sold 3,000 shares of the stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $249.68, for a total transaction of $749,040.00. Following the completion of the sale, the director now directly owns 4,585 shares in the company, valued at $1,144,782.80. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, EVP Paul A. Mahon sold 6,000 shares of United Therapeutics stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $215.01, for a total value of $1,290,060.00. Following the sale, the executive vice president now owns 36,599 shares in the company, valued at $7,869,150.99. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Christopher Causey sold 3,000 shares of the company’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $249.68, for a total transaction of $749,040.00. Following the completion of the transaction, the director now owns 4,585 shares of the company’s stock, valued at $1,144,782.80. The disclosure for this sale can be found here. Insiders have sold a total of 33,605 shares of company stock valued at $7,676,365 in the last quarter. Insiders own 12.50% of the company’s stock.
United Therapeutics Stock Up 1.0 %
Wall Street Analyst Weigh In
A number of research analysts recently commented on UTHR shares. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 1st. Wells Fargo & Company started coverage on United Therapeutics in a report on Friday, December 8th. They set an “overweight” rating and a $309.00 price objective on the stock. SVB Leerink began coverage on United Therapeutics in a research note on Monday. They issued an “outperform” rating and a $330.00 target price for the company. Morgan Stanley decreased their price target on shares of United Therapeutics from $318.00 to $314.00 and set an “overweight” rating on the stock in a research note on Thursday, November 2nd. Finally, Wedbush reaffirmed an “outperform” rating and issued a $308.00 price objective (up previously from $307.00) on shares of United Therapeutics in a research note on Thursday, November 2nd. Ten equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $301.44.
United Therapeutics Profile
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
- Five stocks we like better than United Therapeutics
- Transportation Stocks Investing
- Is the dip in Atlassian stock a sneaky buy opportunity?
- What is a Death Cross in Stocks?
- Caterpillar stock hits new highs; time to ring the register?
- 3 Grocery Stocks That Are Proving They Are Still Essential
- 5 medical stocks growing earnings by triple digits
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.